Medicina

Segui
Medical researchers at University of Calgary reviewing glioblastoma scans alongside niacin supplements for a clinical trial illustration.
Immagine generata dall'IA

Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma

Riportato dall'IA Immagine generata dall'IA Verificato

Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.

A study has identified how an existing medication could improve immunotherapy outcomes for fibrolamellar carcinoma. The rare liver cancer currently has no cure and often spreads before detection. Researchers demonstrated the approach using patient tumor samples.

Riportato dall'IA Verificato

A Newcastle University-led screening study of nearly 300 adults in northern Britain found persistently high rates of low vitamin D in older people and adults from minoritized ethnic groups, with little evidence that summer months substantially improved levels.

Researchers at the University of California, Riverside have proposed that amyloid beta disrupts tau protein function inside neurons, potentially triggering Alzheimer's disease. The findings challenge the focus on external plaques as the primary cause.

Riportato dall'IA

Two existing medications cooled core body temperature in animals after stroke and reduced brain damage. A small human trial showed limited effect due to slow delivery. Researchers are now planning a follow-up study with faster infusions.

Medical technology company SpectraCure in Lund is carrying out a rights issue that will add 34.2 million kronor if fully subscribed. The issue will finance clinical studies and regulatory applications. The share fell more than 20 percent on Monday.

Riportato dall'IA Verificato

Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment, according to a retrospective study presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta